Multiple Presentations at the European Society of Cardiology Congress Document EECP Promotes Coronary Collateral Flow Leading to Sustained Clinical Improvement

WESTBURY, N.Y.--(Business Wire)--
Vasomedical, Inc. ("Vasomedical") (OTC: VASO), a world leader in the noninvasive
treatment of cardiovascular diseases, today announced that evidence presented by
Dr. Eva-Elina Buschmann on behalf of the European Arteriogenesis Network 2
Trial, at the 2009 European Society of Cardiology (ESC) Congress taking place in
Barcelona, Spain, demonstrates that EECP® therapy along with its positive acute
hemodynamic benefits also promotes the growth of coronary collateral blood
vessels to ischemic regions improving circulation in patients with stable
angina.

An oral presentation of the results of a prospective, randomized, controlled,
proof-of-concept study at the ESC conducted by researchers at Charite Hospital
at the University of Berlin confirmed EECP treatment promotes recruitment of new
arteries. The primary end-point, using pressure-derived collateral flow index
during cardiac catheterization, the gold standard to assess myocardial
collateral pathways, demonstrated a significant increase of collateral perfusion
to regions of the myocardium distal to coronary occlusion after EECP treatment.

"These data provide excellent evidence to support the long held hypothesis that
EECP leads to increased myocardial blood flow to ischemic areas of the heart,"
commented Dr. Lawrence Crawford, Associate Clinical Professor of Medicine,
Division of Cardiology, Duke University School of Medicine. He continued, "This
demonstrated that the increase in coronary perfusion, along with the already
published scientific data demonstrating the positive hemodynamic and
neurohormonal effects of EECP therapy, makes a very strong argument for the use
of enhanced external counterpulsation therapy in treating stable angina and
compensated heart failure patients."

Also, presented at the ESC were three additional abstracts demonstrating the
significant improvement in patient functional capacity, i.e. the sustained
symptomatic relief enjoyed by patients following treatment with EECP therapy.
The first study presented by Dr. Youssef A. Beaini is a multicenter study using
patient data collected from four institutions in the United Kingdom - Bradford
Teaching Hospitals NHS Trust in Liverpool, University of Leeds, the
Cardiothoracic Centre NHS Trust in Liverpool, and the Institute for
Cardiovascular Research-Yorkshire Heart Centre in Leeds. This study compared the
pre- and post-EECP treatment results demonstrating significant improvement in
the quality of life measurements including follow up at 6-, 12- and 24-months
post therapy.

The third study presented by Dr. Stefano De Marchi, of the University of
Switzerland in Berne, showed findings of improved myocardial perfusion achieved
by using EECP systems specifically designed to produce high diastolic perfusion
pressure during the application of therapy, confirming the need to have
uniformly applied external pressure with sufficient magnitudes to produce the
beneficial hemodynamic effects of counterpulsation.

The fourth study from the United States presented by Dr. Lisa Kennard,
University of Pittsburgh, demonstrated a marked correlation post-EECP treatment
between improvement of angina functional class expressed by Canadian
Cardiovascular Society (CCS) angina classification and the Duke Activity Status
Index (DASI) score which assesses functional capability in angina patients. The
study showed a significant congruency in assessing functional capacity in
patients with coronary artery disease and multiple comorbidities treated with
EECP therapy.

"Published scientific evidence continues to demonstrate concrete evidence that
the use of EECP treatment provides positive patient outcomes resulting from the
recruitment of collateral blood vessels to ischemic regions, improves
neurohormonal factors, improves endothelial function, reduces proinflammatory
cytokines and adhesion molecules, and reduces arterial stiffness," stated Dr.
Jun Ma, president and CEO of Vasomedical. "All of these combined factors assist
in the improvement of blood flow to ischemic areas and help to explain the life
changing clinical benefits observed in patients that have undergone EECP
therapy. We would like to congratulate the authors of these studies and thank
them for their fantastic work which we believe continues to verify the
hypotheses on the mechanism of actions of EECP therapy. These findings should
lead to wider acceptance and broader use of EECP therapy worldwide," concluded
Dr. Ma.

Except for historical information contained in this report, the matters
discussed are forward-looking statements that involve risks and uncertainties.
When used in this report, words such as "anticipates," "believes," "could,"
"estimates," "expects," "may," "plans," "potential," "should" and "intends" and
similar expressions, as they relate to the Company or its management, identify
forward-looking statements. Such forward-looking statements are based on the
beliefs of the Company`s management, as well as assumptions made by and
information currently available to the Company`s management. Among the factors
that could cause actual results to differ materially are the following: the
effect of business and economic conditions; the effect of the dramatic changes
taking place in the healthcare environment; the impact of competitive procedures
and products and their pricing; medical insurance reimbursement policies;
unexpected manufacturing or supplier problems; unforeseen difficulties and
delays in the conduct of clinical trials and other product development programs;
the actions of regulatory authorities and third-party payers in the United
States and overseas; uncertainties about the acceptance of a novel therapeutic
modality by the medical community; and the risk factors reported from time to
time in the Company`s SEC reports.The Company undertakes no obligation to update
forward-looking statements as a result of future events or developments.

Vasomedical, Inc.
Dr. Jun Ma, President and CEO, 516-997-4600
or
David Singh, CFO, 516-997- 4600
or
Investor Relations:
customerservice@vasomedical.com

Copyright Business Wire 2009